bmj says avastin is just as effective at tackling wet age-related macular degeneration as the current treatment , lucentis .
drug company novartis has been accused of trying to block trials aimed at promoting a ‘ cheap , safe and effective’ treatment for sight loss on the nhs .
avastin is much cheaper and it is estimated that widespread use of the drug would save the nhs around £102million a year .